Adjuvant Radiotherapy in Patients With Early Endometrial Cancer

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jul 2, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the best type of radiation therapy to use after surgery for women with early-stage endometrial cancer, which is cancer of the lining of the uterus. Specifically, the study will compare two types of treatments: vaginal brachytherapy, which delivers radiation directly to the vagina, and pelvic external beam radiotherapy, which targets the pelvic area from outside the body. The goal is to see which method is more effective for patients classified as having a moderate risk of cancer recurrence based on certain biological markers.

To participate in this trial, women aged 65 to 74 who have been diagnosed with a specific type of endometrial cancer (confirmed through pathology tests) may be eligible. Key requirements include having undergone surgery to remove the uterus and ovaries, and not having any serious complications like extensive lymph node involvement. Participants will need to start radiotherapy within 8 weeks of their surgery and will be monitored to ensure they are in good health. It's important to note that this trial is not yet recruiting participants, so it’s a great opportunity for those who fit the criteria to potentially benefit from new treatment insights in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type;
• • 2. Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion;
• • 3. Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional;
• • 4. ECOG score is 0-2;
• • 5. The interval time between surgery and radiotherapy is no more than 8 weeks;
• • 6. The routine blood examination was normal;
• • 7. Compliance is good and informed consent is voluntarily signed.
• Exclusion Criteria:
• • 1. The patients receive chemotherapy;
• • 2. History of previous malignant disease;
• • 3. Previous diagnosis of Crohn's disease or ulcerative colitis.